Lipid Yönetiminde Yeni Dönem: ApoB Merkezli Yaklaşımlar ve Gelişen Tedaviler

Öz

Aterosklerotik kardiyovasküler hastalık (ASCVD), temelde apolipoprotein B (apoB) içeren lipoproteinlere yaşam boyu maruziyetin kümülatif bir sonucudur. Genetik epidemiyoloji, Mendel randomizasyon çalışmaları ve geniş ölçekli randomize klinik çalışmalar, düşük yoğunluklu lipoprotein kolesterolü (LDL-K) ve apoB partikül yükünün ateroskleroz için nedensel belirleyiciler olduğunu açık biçimde ortaya koymuştur. Bu doğrultuda güncel lipid tedavisi, klasik statin merkezli ve basamaklı yaklaşımdan uzaklaşarak daha erken başlanan, daha derin ve bireyselleştirilmiş stratejilere yönelmiştir. Statinler lipid düşürücü tedavinin temelini oluşturmaya devam etse de, çok yüksek riskli hastalarda hedeflere ulaşmada yetersiz kalabilmeleri ve statin intoleransı, yeni ilaç sınıflarının klinik pratiğe girmesini hızlandırmıştır. Proprotein konvertaz subtilisin/keksin tip 9 (PCSK9) monoklonal antikorları, statin tedavisine eklendiğinde belirgin LDL-K düşüşü ve kardiyovasküler olaylarda anlamlı azalma sağlamaktadır. Küçük girişimci RNA (siRNA) temelli tedaviler, özellikle inclisiran, seyrek dozlama ile kalıcı LDL-K düşüşü sunarak tedavi uyumu sorununa yenilikçi bir çözüm getirmektedir. Bempedoic acid, statin intoleransı olan hastalarda olay azaltıcı etkisi kanıtlanmış bir alternatif olarak öne çıkarken, anjiyopoietin benzeri protein 3 (ANGPTL3) inhibisyonu LDL reseptöründen bağımsız lipid düşüşü sağlayarak ailesel hiperkolesterolemide önemli bir seçenek sunmaktadır. LDL-K’nin ötesinde, lipoprotein(a) [Lp(a)] genetik olarak belirlenen, bağımsız ve nedensel bir kardiyovasküler risk faktörü olarak giderek daha fazla önem kazanmaktadır. Lp(a)’yı hedefleyen yeni nesil antisens ve siRNA tedavileri, rezidüel kardiyovasküler riskin azaltılmasında gelecek vaat eden bir yaklaşım olarak lipidolojide yeni bir dönemin habercisidir.

Anahtar Kelimeler

• Apolipoprotein B
• LDL-kolesterol
• aterosklerotik kardiyovasküler hastalık
• PCSK9 inhibitörleri
• inklisiran
• lipoprotein(a)
• bempedoik asit

The new landscape of lipid management: apoB-centered strategies and emerging therapies

Öz

Atherosclerotic cardiovascular disease (ASCVD) is primarily driven by cumulative lifetime exposure to apolipoprotein B (apoB)–containing lipoproteins. Converging evidence from genetic studies, Mendelian randomization analyses, and large randomized clinical trials has firmly established low-density lipoprotein cholesterol (LDL-C) and apoB particle burden as causal determinants of atherosclerosis. Accordingly, contemporary lipid management has shifted from a traditional statin-centered, stepwise paradigm toward strategies emphasizing earlier initiation, deeper lipid lowering, and individualized treatment based on patient-specific biological risk. Although statins remain the foundation of lipid-lowering therapy, their limitations in very-high-risk populations and in patients with statin intolerance have driven the development of novel therapeutic agents. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies provide substantial additional LDL-C reduction and have demonstrated significant cardiovascular event reduction in secondary prevention settings. Small interfering RNA (siRNA)–based therapies, particularly inclisiran, offer durable LDL-C lowering with infrequent dosing, addressing challenges related to long-term adherence. Bempedoic acid has emerged as an outcome-proven alternative for statin-intolerant patients, while angiopoietin-like protein 3 (ANGPTL3) inhibition enables LDL receptor–independent lipid lowering, expanding therapeutic options for patients with familial hypercholesterolemia. Beyond LDL-C, lipoprotein(a) [Lp(a)] has gained recognition as a genetically determined, independent, and causal cardiovascular risk factor. Novel antisense oligonucleotide and siRNA-based therapies targeting Lp(a) achieve profound reductions in circulating levels and represent a promising approach to residual cardiovascular risk, with large outcome trials currently underway. Collectively, recent advances in lipid therapeutics support a paradigm shift toward precision lipid management, focused on lifelong reduction of atherogenic particle burden and comprehensive cardiovascular risk modification.

Anahtar Kelimeler

• Apolipoprotein B (apoB)
• LDL-cholesterol
• atherosclerotic cardiovascular disease (ASCVD)
• PCSK9 inhibitors
• inclisiran
• lipoprotein(a)
• bempedoic acid

Kaynakça

1. Baigent C, Blackwell L, Emberson J, Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation. 2019;139:e1082–e1143.
3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41:111-88.
4. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering. J Am Coll Cardiol. 2022;80:1366-418.
5. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021;78:960-93.
6. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372:2387-97.
7. Kim BK, Hong SJ, Lee YJ, et al. A strategy of high-intensity statin therapy versus moderate-intensity statin therapy in patients with coronary artery disease (LODESTAR). Lancet. 2022;400:380-90.
8. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with statin intolerance. JAMA. 2016;315:1580-90.

9. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500-9.
10. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376:1713-22.
11. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379:2097-107.
12. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10 and ORION-11). N Engl J Med. 2020;382:1507-19.
13. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520-30.
14. Ray KK, Wright RS, Kallend D, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40.
15. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388:1353-64.
16. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99.
17. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380:11-22.
18. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (STRENGTH). JAMA. 2020;324:2268-80.
19. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk (PROMINENT). N Engl J Med. 2022;387:1923-34.
20. Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383:2307-19.
21. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711-20.
22. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease (AKCEA-APO(a)-LRx). N Engl J Med. 2020;382:244-55.
23. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a) reduction with olpasiran in patients with atherosclerotic cardiovascular disease (OCEAN(a)-DOSE). N Engl J Med. 2022;387:1855-64.
24. Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of SLN360, an siRNA targeting lipoprotein(a). JAMA. 2022;327:1679-87.
25. Nissen SE, Linnebjerg H, Shear C, et al. Antisense inhibition of apolipoprotein(a) with lepodisiran in patients with elevated lipoprotein(a). N Engl J Med. 2025;392:1673-83.
26. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).